Journal
FASEB JOURNAL
Volume 25, Issue 7, Pages 2447-2455Publisher
FEDERATION AMER SOC EXP BIOL
DOI: 10.1096/fj.10-174284
Keywords
macrophage; C5a receptor; PMX53
Categories
Funding
- Australia National Health and Medical Research Council
- British Heart Foundation
- Deutsche Forschungsgemeinschaft [ZE827/4-1]
Ask authors/readers for more resources
The complement C5a receptor, CD88, is present on many of the cells found within human atherosclerotic plaques, but little is known about the role of C5a in atherogenesis. Using real-time PCR, we determined that ApoE(-/-) mice fed a normal diet express more aortic CD88 mRNA compared with controls, and this increase coincides with atherosclerotic lesion development (P<0.001 for 3- vs. 25-wk-old animals). Conversely, mRNA expression of the alternative C5a receptor, C5L2, in aortas of ApoE(-/-) mice, was lower than controls at all time points. Using immunohistochemistry, we confirmed the presence of CD88 on macrophages, smooth muscle cells, and activated endothelial cells in plaques from brachiocephalic arteries. Treatment of ApoE(-/-) mice with a CD88 antagonist (PMX53; 3 mg/kg s.c. 3 x /wk plus 1 mg/kg/d p.o.) for 25 wk reduced lesion size and lipid content in the plaque by similar to 40% (P<0.05). Our study provides evidence for a proatherogenic role for C5a and identifies the CD88 antagonist PMX53 as a potential antiatherosclerotic drug.-Manthey, H. D., Thomas, A. C., Shiels, I. A., Zernecke, A., Woodruff, T. M., Rolfe, B., Taylor, S. M. Complement C5a inhibition reduces atherosclerosis in ApoE(-/-) mice. FASEB J. 25, 2447-2455 (2011). www.fasebj.org
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available